OncoMatch/Clinical Trials/NCT04870944
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Is NCT04870944 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies FACT Complex-targeting Curaxin CBL0137 for diffuse midline glioma, h3 k27-altered.
Treatment: FACT Complex-targeting Curaxin CBL0137 — This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Intrinsic Pontine Glioma
Tumor Agnostic
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Disease stage
Metastatic disease required
Metastatic Malignant Neoplasm in the Central Nervous System
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: CBL0137 (CBL0137)
Patients must not have received prior exposure to CBL0137
Lab requirements
Blood counts
ANC >= 1000/uL; Platelet count >= 100,000/uL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
Kidney function
Creatinine clearance or radioisotope GFR >= 70 mL/min/1.73 m^2 or a creatinine based on age/sex
Liver function
Bilirubin (sum of conjugated + unconjugated or total) <= 1.5 x ULN for age; SGPT (ALT) <= 135 U/L (ULN for SGPT is 45 U/L)
Cardiac function
Shortening fraction of >= 27% by echocardiogram or ejection fraction of >= 50% by gated radionuclide study; Corrected QT (QTC) < 480 msec
See inclusion criteria for full details on organ function requirements
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Alabama · Birmingham, Alabama
- Phoenix Childrens Hospital · Phoenix, Arizona
- Children's Hospital Los Angeles · Los Angeles, California
- Children's Hospital of Orange County · Orange, California
- UCSF Medical Center-Mission Bay · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04870944 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CBL0137 disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify